Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.
Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) is indicated to lower IOP in adults with primary open-angle glaucoma or ocular hypertension in whom prostaglandin or netarsudil monotherapy does not provide a sufficient decrease.
“The authorization of Roclanda in Great Britain, the only fixed-dose combination IOP-lowering therapy with a prostaglandin analogue that does not include a beta